Biogen CEO Michel Vounatsos saw a boost in his compensation package in 2018, as the board rewarded him for record revenues. But now that the company's key pipeline asset has failed, Vounatsos is under pressure to come up with a new R&D plan.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,